INTRODUCTION
Effective therapeutic agents, such as calcineurin inhibitors, exist for the prevention of transplant rejection, but they possess numerous and significant dose-limiting toxicities, thereby creating a need for agents with novel immunosuppressive mechanisms of action [1] . The inhibition of Janus kinase 3 (JAK3) represents an attractive strategy for immunosuppression based on its limited tissue distribution, its lack of constitutive activation, and its role in immune cell function [2] . JAK3 is a cytoplasmic protein tyrosine kinase associated with the common ␥ chain (␥c), an integral component of receptors of the interleukin (IL)-2 cytokine family. Members of this family include IL-4, IL-7, IL-9, and IL-15, all of which use the JAK-signal transducer and activator of transcription pathway for intracellular signaling [3] . These cytokines are critical for lymphocyte differentiation, survival, and function. The X-linked form of severe combined immunodeficiency (SCID) has mutations in ␥c that resulted in the absence of T and natural killer (NK) cells [4, 5] Similarly, a patient with defective expression of the IL-2/IL-15 receptor ␤ (IL-2R␤/IL-15R␤) subunit had a NK cell-deficient form of SCID [6] . In mice, the genetic ablation of JAK3 or ␥c leads to dramatic defects in T, B, and NK cell development [7] [8] [9] .
CP-690550 is a recently described selective, small molecule inhibitor of JAK3. It is a potent inhibitor of immune responses in such in vitro assays as IL-2-mediated human T cell blast proliferation [inhibitory concentration 50% (IC 50 )ϭ11 nM] and mixed lymphocyte reaction (IC 50 ϭ87 nM) [10] . In vivo studies demonstrated that CP-690550 reduced a delayed-type hypersensitivity response and extended cardiac allograft survival in murine models [11] . Analysis of circulating lymphocyte subsets in mice receiving chronic CP-690550 dosing revealed reductions in T, B, and NK cell numbers, which were consistent with the phenotype of ␥c and JAK3 knockout (KO) mice [7] [8] [9] . As IL-7 is an important regulatory cytokine for T and B cell development in this species, some of the lymphoid effects could be attributed to blockade of IL-7R signaling by CP-690550 [12, 13] . In addition, the loss of NK cells is consistent with the known role of IL-15 for their homeostasis [14 -16] .
CP-690550 also demonstrated robust extension of life-supporting kidney allograft survival in cynomolgus monkeys [10] . Given species differences that exist for cytokines in lymphocyte development, we explored the effects of this novel JAK3 inhibitor on lymphocyte subsets in the peripheral blood of nonhuman primates following chronic oral administration. The selective reduction in NK and CD8ϩ T cells observed following JAK3 inhibition is consistent with the ability of the compound to block IL-15R signaling and function. These data may provide not only a biomarker for CP-690550 activity but may also improve our understanding of the mechanism(s) by which JAK3 inhibition prolongs allograft survival in this species.
MATERIALS AND METHODS

Reagents
CP-690550 was synthesized at Pfizer Global Research and Development (Groton, CT). The following antibodies (clone designation) were obtained from BD Biosciences (San Jose, CA) or PharMingen (San Diego, CA): for cynomolgus monkeys, CD3ε (SP34) phycoerythrin (PE), CD4 (L200) peridinin chlorophyll protein (PerCP), CD8␣ [ribonuclease protection assay (RPA)-TA] fluorescein isothioycanate (FITC) or allophycocyanin (APC), CD8␣ (SK1) PerCP, CD16 (3G8) FITC, CD20 (2H7) FITC, CD28 (CD28.2) FITC, CD69 (FN50) PerCP, CD95 (DX2) APC, integrin ␤7 (FIB504) PE; and for human studies, CD3 (SK7) PerCP, CD16 (3G8) PE, CD56 (B159) PE, CD8 (RPA-TA) APC. CD69 (CH/4) FITC from Caltag (Burlingame, CA) was used in the whole blood, IL-15-mediated CD69 induction assay. CD8␤ (2ST8.5H7) PE was purchased from Immunotech (Marseille, France).
Animals
Mauritius-origin adult cynomolgus monkeys (Macaca fascicularis) were used in these experiments. Animals weighed between 3.5 and 8.8 kg, were in good clinical health, and acclimated to the venipuncture and oral dosing procedures prior to initiation of the studies. All procedures were in strict accordance with the guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Numbers of male and female animals were evenly distributed between the treatment groups. CP-690550 was prepared in 0.5% methylcellulose in distilled water and administered twice daily (12 h apart) by oral gavage.
Lymphocyte phenotyping
Monkey whole blood was collected into EDTA microtainer tubes. Total leukocyte counts of cynomolgus whole blood were determined using an Abbott Cell-Dyn 3500 (Abbott Laboratories, Abbott Park, IL). The following antibody panels were used: CD16 FITC ϫ CD3 PE ϫ CD4 PerCP ϫ CD8␣ APC or CD20 FITC ϫ CD3 PE. Manufacturer-recommended isotype controls were used. Numbers of specific lymphocyte subsets were calculated by multiplying the total white blood cell counts by the percent total of each specific lymphocyte subset. Baseline values were determined by averaging two independent measurements obtained at least 2 weeks prior to treatment commencement. Effects of compound administration on lymphocyte subsets were expressed as a percent of the baseline determination.
IL-15-mediated induction of CD69 expression
Heparinized human or cynomolgus monkey blood was incubated with various concentrations of human recombinant IL-15 (R&D Systems, Minneapolis, MN) for 4 h at 37°C. The antibody panel used for human blood studies was CD69 FITC ϫ CD16 PE and CD56 PE ϫ CD8␣ APC. For cynomolgus blood studies, the panel used was CD8 FITC ϫ CD3 PE ϫ CD4 PerCP ϫ CD69 APC. In these studies, cynomolgus NK cells were defined as CD8ϩ CD3-cells. To compare CD69 up-regulation on naïve versus memory CD8ϩ T cells, the following antibody panel was used: CD28 FITC ϫ CD8␤ PE ϫ CD69 PerCP ϫ CD95 APC. To determine effects of CP-690550, whole blood was first incubated at 37°C for 5 min with varying concentrations of compound then incubated with IL-15 (10 ng/ml) for 4 h at 37°C.
Fluorescein-activated cell sorter (FACS) analysis
Fluorescent immunostaining was quantitated using a Becton Dickinson FACSCalibur equipped with a 488 argon laser and a 635-nm red diode laser. Data acquisition and analyses were performed using CellQuestPro software (BD Biosciences). For phenotypic analyses, 10,000 lymphocytes gated by lightscatter profile were collected. For the IL-15-mediated CD69 up-regulation studies, data acquisition was terminated after 2500 gated NK cells were acquired.
Statistics
Statistical analysis of changes in lymphocyte subsets was performed by oneway ANOVA. Significance was defined as P Ͻ 0.05.
RESULTS
Chronic administration of CP-690550 decreases circulating NK and CD8ϩ T cell numbers in cynomolgus monkeys in a dose-and timedependent manner Cynomolgus monkeys received CP-690550 (30 mg/kg/d) or vehicle by oral gavage for 21 days. Total circulating white blood cell counts were affected modestly, and reductions were only in lymphocyte numbers (58.2Ϯ4.85% of pretreatment levels at 21 days) in those animals treated with the JAK3 inhibitor relative to vehicle-treated animals at the same time (83.5Ϯ5.67% of baseline). There were no significant differences between treatment groups for other measured hematological parameters ( Table 1) . Peripheral blood NK, B, and CD8ϩ and CD4ϩ T cells were enumerated beginning 4 days following the initial dose. During 3 weeks of repeated, daily CP-690550 dosing, NK cell numbers decreased progressively with time and reached a nadir of 21.1 Ϯ 3.01% predose values (relative to 64.9Ϯ7.44% following vehicle treatment) on day 21 post-administration (Fig. 1A) . Within 3 weeks following cessation of dosing, NK cell numbers in CP-690550-treated animals returned to levels observed in vehicle-treated animals. A small but significant reduction in CD8ϩ cells was also observed in CP-690550-treated animals during the same period (Fig. 1B) . However, a marked rebound (300% increase) in CD8ϩ T cell number was observed 14 days after administration of the final dose and returned to levels in vehicle-treated animals ϳ3 weeks later. B cell numbers (Fig. 1C ) in monkeys receiving CP-690550 at 30 mg/kg/d were increased moderately relative to vehicle-treated animals throughout the entire observation periods. CD4ϩ T cells numbers (Fig. 1D) were not significantly different between treatment groups for the first 21 days of treatment. However, after cessation of CP-690550 dosing, the CD4ϩ T cell number increased 225% over baseline, which was coincidental with the increase of the CD8ϩ cells.
To determine whether the decline in NK cell numbers was dose-dependent, CP-690550 or vehicle was administered for 14 days at doses of 1, 10, or 30 mg/kg/d. Peripheral blood NK (Fig. 2) . NK cell effects were not observed in animals receiving CP-690550 for a single day, even at doses up to 200 mg/kg (data not shown).
Circulating CD8ϩ memory cell numbers are preferentially affected following chronic CP-690550 administration to cynomolgus monkeys
The small decrease in the circulating CD8ϩ T cell number, which occurred during CP-690550 administration, raised the question of whether this was a general effect on all CD8ϩ T cells or a function of increased sensitivity of a particular lymphocyte subset to JAK3 inhibition. Pitcher et al. [17] used an extensive panel of antibodies to delineate naïve versus memory CD4ϩ and CD8ϩ cells in rhesus monkeys. The different T cell memory subsets were profiled further by in vivo and in vitro functional studies into central and effector memory cells. Although these studies used rhesus monkey, the authors noted their analytical methodology was applicable to cynomolgus monkeys. We selected a combination of the two antibodies, CD28 and CD95, from this panel to delineate cynomolgus monkey T cells into naïve, putative effector memory and putative central memory cell populations (Fig. 3) . Following a 2-week treatment with CP-690550 10 mg/kg/d, naïve, central memory, or effector memory CD4ϩ T cell numbers did not differ significantly between the two treatment groups (Fig. 4A) . When CD8ϩ T cells from the same animals were examined, equivalent numbers of naïve and central memory CD8ϩ cells were detected in the peripheral blood of each group. However, effector memory CD8ϩ cell numbers in the CP-690550-treated group were 55% less than those observed in animals treated with vehicle (Fig. 4B) .
CP-690550 inhibits IL-15-induced CD69 expression in human and cynomolgus monkey NK and CD8ϩ T cells in vitro
The preferential effect of CP-690550 on circulating NK and memory CD8ϩ T cell numbers is consistent with a role for IL-15 in their homeostasis. To verify that the JAK3 inhibitor affected cell responses to this cytokine, the ability of CP-690550 to inhibit IL-15-induced CD69 expression on NK and CD8ϩ T cells was determined in monkey and human whole blood in vitro. IL-15 induced CD69 expression on NK cells and CD8ϩ T cells in a dose-dependent manner (Fig. 5) . IL-15 potency was similar in human versus monkey cells ( Table 2 ).
The percentage of NK cells in human whole blood expressing CD69 increased from an average of 17.2% to 66.9% following 4 h incubation with 10 ng/ml IL-15. In cynomolgus whole blood, the percentage of NK cells expressing CD69 increased from an average of 34.2% to 71.5%. Fewer CD8ϩ T cells responded to IL-15 in human (from 3.7% to 13.7%) and cynomolgus monkey (from 3.7% to 9.1%) whole blood. When CD8ϩ subtype sensitivity to IL-15 was examined in cynomolgus monkey blood, a greater percentage of effector memory cells exhibited responsiveness to IL-15 (22.7Ϯ5.01%) relative to central (8.68Ϯ1.03%) and naïve CD8ϩ T cells (0.84Ϯ0.20%; Fig. 6A ). However, CD69 expression on central memory cells increased to a greater extent (8.01Ϯ1.45ϫbase-line) than did effector memory cells (4.39Ϯ0.77ϫbaseline; Fig. 6B ). CD69 expression on CD4ϩ T cells was not modified by the cytokine (data not shown).
CP-690550 potently inhibited IL-15-induced CD69 expression on NK and CD8ϩ T cells in a concentration-dependent manner (Fig. 7) . Potency of the compound in human whole blood was similar to cynomolgus monkey and in both species, appeared slightly more potent in CD8ϩ T cells versus NK Fig. 3 . Flow cytometric analysis of cynomolgus CD4ϩ and CD8ϩ memory and naïve T cells. Memory and naïve circulating lymphocyte subsets were determined and defined by an antibody panel as described previously [17] . The fluorescent profiles of gated CD4ϩ (A) and gated CD8ϩ (B) naïve (CD28 med/high CD95 neg/low , green dots) and putative central memory (CD28 med/high CD95ϩ, red dots) and putative effector memory T cells (CD28 neg/low CD95ϩ, blue dots) are presented. cells. In cynomolgus monkeys, CP-690550 potency was no different between central (IC 50 ϭ26.2Ϯ4.3 nM; nϭ4) and effector (IC 50 ϭ21.7Ϯ3.4 nM; nϭ4) memory CD8ϩ T cells (Fig. 8) .
DISCUSSION
Chronic administration of the JAK3 inhibitor CP-690550 to cynomolgus monkeys produced a selective and reversible reduction in circulating NK and CD8ϩ T cell numbers, the latter being primarily of the memory phenotype. This effect was significantly greater than that observed in vehicle-treated animals, the latter being attributed to stress resulting from animal handling [18, 19] . The CP-690550-induced decrease in NK cells and CD8ϩ T cells is consistent with the phenotype exhibited by SCID patients with JAK3 deficiency, i.e., reduced NK and CD8ϩ T but not B cells [20] . The affected cell populations differ somewhat from those previously reported in mice receiving chronic CP-690550 treatment. In the murine studies, as in JAK3 KO mice, B, NK, as well as CD4ϩ and CD8ϩ T cell numbers were reduced relative to vehicle-treated animals [11] . However, these murine studies with CP-690550 did reveal a differential sensitivity of NK and CD8ϩ cells to CP-690550, which was manifested by an accelerated rate and an increased magnitude of their decline relative to other cell types. It is likely that some of the broader effects produced by the compound on murine lymphocyte numbers resulted from the role of IL-7 as a pre-B cell growth factor in mice. In humans, the immunological profiles of SCID patients exhibiting defective IL-7R expression suggest that this cytokine is only partially required for T cell development and dispensable for B cell development [12, 13, 21] . Despite myriad cytokines that affect lymphocyte homeostasis, the selective reduction in NK and memory CD8ϩ T cells observed following CP-690550 administration to cynomolgus monkeys is consistent with emerging data about the importance of IL-15 for the homeostasis of these cells. Mice genetically deficient in IL-15 or IL-15R subunits exhibited selective defects in NK and CD8ϩ T cells, the latter being primarily of the memory phenotype [15, 16] . Conversely, transgenic mice that overexpressed IL-15 had expanded populations of the same cells [22] . Of the lymphocyte subsets affected by this cytokine, NK cell development appears most dependent, a response that may be related to the degree of CD122 expression on these cells [23, 24] . In our experiments, the decline in peripheral NK cell numbers appeared within 1 week of initiating JAK3 inhibition and suggests effects on cell processes other than development alone. IL-15 has been shown to be important for the survival of mature NK cells, an effect that appears mediated via Bcl-2 [14, 25] . This cytokine also prevented apoptosis of human NK cells in a dose-dependent manner and was capable of sustaining survival of these cells for up to 8 days in the absence of serum [26] . To verify that CP-690550 does affect IL-15 signaling, we demonstrated its ability to inhibit in vitro CD69 up-regulation in cell populations affected by the compound in vivo. In fact, CP-690550 plasma levels achieved following doses of 10 and 30 mg/kg/d were 19.9 ng/ml and 73 ng/ml, respectively, which is nearly equal to or exceeded the Heparinized human (nϭ6 for NK cells, and nϭ5 for CD8ϩ T cells) or cynomolgus monkey (nϭ7) blood was incubated with various concentrations of IL-15 for 4 h at 37°C. Samples were washed, and CD69 expression on NK and CD8ϩ T cells was determined by FACS analysis as described in Materials and Methods. EC 50 , effective concentration 50%.
IC 90 of the compound for inhibition of IL-15-induced upregulation on NK cells (240Ϯ49.6 nM; nϭ4). NK cell expansion and differentiation are promoted by IL-21, another cytokine that uses JAK3 signaling and synergizes with IL-15 [27] . It is possible that CP-690550 produced some of its effects via inhibition of this cytokine's signaling as well.
Chronic CP-690550 administration also significantly reduced the number of circulating memory CD8ϩ T cells. These data cannot simply be explained by the fact that memory lymphocytes have a more rapid background rate of proliferation than naïve cells [17, 28] , as CD4ϩ memory T cell numbers were unaffected during the treatment period. At least two ␥c cytokines have been shown to be responsible for CD8ϩ memory cell development: IL-7 and IL-15, the signaling of which would be affected by JAK3 inhibition. In the absence of IL-15, CD8ϩ memory T cells gradually decline in number as a result of reduced cell proliferation; it has been proposed that nearly 80% of memory phenotype CD8ϩ T cells proliferate within a 5-week period [28] . Murine CD8ϩ memory cells can use IL-7 or IL-15 to undergo homeostatic proliferation, which fails to occur in the absence of both [29] . Continued survival of memory CD8ϩ T cells also appears to rely on these cytokines. IL-15 modulates the expression of the antiapoptotic protein Bcl-2 in these cells [30] . Depletion of IL-7 also reduces memory cell survival in vivo, although less consistently or potently as IL-15 [31] . In fact, increased expression of the IL-7R␣ chain identifies CD8ϩ T cells, which will differentiate into memory cells [32] . It is interesting that a marked increase was observed in CD8ϩ T cell numbers following discontinuation of CP-690550 treatment. However, naïve versus memory T cells were not analyzed at this stage; therefore, it is unknown whether the increase represented a general proliferation of T cells or of specific subpopulations. It is possible that the rebound effect occurred as a result of increased IL-7 levels, which have been reported upon T cell depletion [33] concurrent with reversal of blockade of IL-7R signaling. The cytokine has been shown to increase proliferation of peripheral T cells in nonhuman primates, thereby increasing peripheral homeostatic proliferation [34] . Although CP-690550-treated animals did not demonstrate a decline in peripheral CD4ϩ T cell number during the 21 days of compound administration, an increase in these cells (Ͼ200% of baseline) occurred within 2 weeks after termination of compound administration. This effect was not observed in the vehicle control group and paralleled the CD8ϩ T cell increase, consistent with the hypothesis that there was an overproduction of a cytokine such as IL-7, which promotes CD4ϩ and CD8ϩ T cell proliferation [35] .
CP-690550 monotherapy significantly improved renal allograft survival in nonhuman primates when administered at doses comparable with those described here [10] . Given the broad range of cytokines affected as a consequence of JAK3 inhibition, the precise molecular mechanism responsible for efficacy may be difficult to ascertain. However, it is clear that CP-690550 affected NK and CD8ϩ T cell numbers, both of which may play a role in allograft rejection. It has been suggested that long-term allograft survival in humans is impaired as a result of the persistence of memory T cells, which may be resistant to currently used immunosuppressive therapies [36] . NK cells have been implicated in rejection of bone marrow allografts [37] as well as solid organ transplants [38] . Administration of CP-690550 to cynomolgus monkeys has also been shown to affect cell function as measured by its ability to attenuate IL-2-induced interferon-␥ production, CD25 expression, and proliferation in lymphocytes [10] .
In conclusion, these studies have demonstrated a reduction in selected circulating lymphocyte subsets following JAK3 inhibition by the small molecule inhibitor CP-690550. These findings are consistent with the SCID phenotype observed in humans with disrupted JAK3 signaling. Interruption of the IL-15R as well as IL-7R signaling and hence their concomitant functions may play an important role in the immunosuppressive effects observed following CP-690550 administration. The depletion of NK cells and a subset of CD8ϩ T cells, in combination with other effects on lymphocyte functions described previously [10] , contributes to the robust efficacy observed in nonhuman renal transplant models and supports the promise of CP-690550 as a valuable therapy for the treatment of human allograft rejection. Fig. 8 . IL-15-induced CD69 expression in cynomolgus central and memory CD8ϩ T cells was equally sensitive to inhibition by CP-690550. Heparinized whole blood from untreated cynomolgus monkeys (nϭ4) was incubated with CP-690550 at 37°C for 5 min followed by a 4-h incubation with 10 ng/ml IL-15 at 37°C. CD69 expression was determined and expressed as percent control samples that had not been treated with CP-690550.
